Sumain Faisal

BioMarin Discontinues Preclinical Drug Candidate, Advances BMN 333 Toward 2030

BioMarin beats Q2 expectations on strong enzyme therapy sales and raises full-year earnings and revenue guidance amid continued Voxzogo growth. Latest Ratings for BMRN Date Firm Action From To Feb 2022 Piper Sandler Maintains Overweight Nov 2021 Credit Suisse Maintains Outperform Nov 2021 Morgan Stanley Maintains Equal-Weight View More Analyst Ratings for BMRN View the…

Read More